Companies · TXG
10x Genomics
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 6, 2026
10x Genomics Q3 2026: Consumables and gross margin expand sharply as instrument revenue collapses 43% and Atera enters first shipments
10x Genomics delivered Q3 2026 products and services revenue of $150.2 million, up 1% year-over-year, entirely on the strength of consumables — which rose 5% to $134.3 million — while instrument revenue fell 43% to $6.9 million as customers deferred Xenium and Visium purchases ahead of Atera. Gross margin expanded to 75% from 67% a year earlier, driven by $5.9 million lower inventory write-downs and reduced manufacturing costs, marking a structural improvement in cost execution. The Atera spatial platform began shipping in September 2026, creating a product transition period where instrument-heavy revenue mix will compress gross margin in Q4 2026 even as the installed base begins to build.
Tone: mixedRevenue
$642.8M
TXG 10-K · FY 2025
Employees
1,178
Revenue growth YoY
+5%
Founded
2012
Profile
TXG 10-K Item 1 · Feb 13, 202610x Genomics is a life sciences technology company that develops instruments, consumables and software enabling researchers to analyze biological systems at single-cell and spatial resolution. Its two product portfolios — Single Cell (Chromium platform) and Spatial (Visium and Xenium platforms) — serve academic, government and biopharmaceutical customers in over 50 countries. The company has sold 8,046 cumulative instruments since its first product launch in mid-2015.
Read filing description ↓ Collapse description ↑
Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience. Since launching our first product in mid-2015 through December 31, 2025, we have sold 8,046 instruments to researchers around the world, including academic and translational researchers and biopharmaceutical companies. Our commercial product portfolio is made up of our Single Cell and Spatial solutions. Our products include our instruments, which include our Chromium instruments, our Visium CytAssist and our Xenium Analyzer, and our consumables, which include proprietary microfluidic chips, slides, reagents and other consumables for our Single Cell and Spatial solutions. We bundle our software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. Customers purchase instruments and consumables from us for use in their experiments. We also derive revenue from post-warranty service contracts for our instruments.
Primary products
- Chromium X Series
- Chromium instruments
- Visium CytAssist
- Xenium Analyzer
- QuantumScale Single Cell RNA kits
- Single Cell Methylation kits
Business segments
End markets
Geographies
Named customers
For the years ended December 31, 2025 and 2024, no single customer, including distributors, represented greater than 10% of our business.
Named competitors
“We believe we are differentiated from our competitors for many reasons, including the capabilities and performance of our products, our advanced proprietary technologies protected by substantial intellectual property, our rigorous product development processes and scalable infrastructure and our superior customer experience and multidisciplinary teams.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue increased 5% year-over-year to $642.8 million in 2025, driven primarily by $46.1 million in license and royalty revenue (versus $0.3 million in 2024), partially offset by a modest decline in products and services revenue.
The rest of TXG is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.